Archit Organosys

Who are in the management team of Archit Organosys?

As of March 2020, the management team of Archit Organosys includes Kandarp K Amin (Chairman & Wholetime Director), Archana K Amin (Whole-time Director), and several non-executive directors, along with company secretaries Anchal Bansal and Vijay A. Boliya. The team consists of both executive and non-executive members overseeing the company's governance and operations.

As of March 2020, the management team of Archit Organosys includes the following individuals:<BR><BR>1. Kandarp K Amin - Chairman & Wholetime Director<BR>2. Archana K Amin - Whole-time Director<BR>3. Bhupendra Mehta - Non-Executive & Independent Director<BR>4. Rajendraprasad J Shah - Non-Executive & Independent Director<BR>5. Archit Amin - Whole-time Director<BR>6. Anchal Bansal - Company Secretary<BR>7. Shreeraj Desai - Additional Non-Executive & Independent Director<BR>8. Nikul Jagdishchandra Patel - Additional Director<BR>9. Vijay A. Boliya - Company Secretary<BR><BR>This team comprises a mix of executive and non-executive members, contributing to the governance and operational management of the company.

What does Archit Organosys do?

Archit Organosys Ltd manufactures and trades chemical products in the commodity chemicals industry, with a market cap of Rs 91 Cr. As of March 2025, it reported net sales of 43 Cr and a net profit of 2 Cr.

Overview: <BR>Archit Organosys Ltd is engaged in the manufacturing and trading of various chemical products within the commodity chemicals industry and operates in the micro-cap market.<BR><BR>History: <BR>The company was originally incorporated on 04th August 1993 as "Shri Chlochem Limited" and changed its name to Archit Organosys Limited effective from 19th May 2012. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 43 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 2 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 91 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 91.00 <BR>Industry P/E: 47 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.35 <BR>Return on Equity: 0.97% <BR>Price to Book: 1.42 <BR><BR>Contact Details: <BR>Address: Plot No 25/9/A Phase III, G I D C Naroda Ahmedabad Gujarat : 382330 <BR>Tel: 91-079-2821154 <BR>Email: share@architorg.com <BR>Website: http://www.architorg.com

Has Archit Organosys declared dividend?

Yes, Archit Organosys Ltd has declared a 5% dividend, amounting to ₹0.5 per share, with an ex-date of August 8, 2023. The current dividend yield is 0%, and total returns have varied significantly across different periods, with a notable increase of 333.44% over the past five years.

Archit Organosys Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 08 Aug 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>Over the 6-month period, the price return was -4.8%, the dividend return was 0%, resulting in a total return of -4.8%.<BR><BR>In the 1-year period, the price return was 6.78%, the dividend return was 0%, leading to a total return of 6.78%.<BR><BR>For the 2-year period, the price return was -34.63%, the dividend return was 0.80%, culminating in a total return of -33.83%.<BR><BR>During the 3-year period, the price return was -6.83%, the dividend return was 2.90%, resulting in a total return of -3.93%.<BR><BR>In the 4-year period, the price return was -0.25%, the dividend return was 4.11%, leading to a total return of 3.86%.<BR><BR>Over the 5-year period, the price return was 317.05%, the dividend return was 16.39%, resulting in a total return of 333.44%.<BR><BR>Overall, Archit Organosys has declared a dividend, but the dividend yield is currently at 0%. The total returns show significant variability, with a notable increase over the 5-year period, contrasting with the negative returns in shorter time frames.

Who are the peers of the Archit Organosys?

Peers of Archit Organosys include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Polychem, Shreyas Interm., Sh. Hari Chem., and Gayatri BioOrga. Archit Organosys has below-average management risk and good growth, with a 1-year return of 6.22%.

Peers: The peers of Archit Organosys are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Polychem, Shreyas Interm., Sh. Hari Chem., and Gayatri BioOrga.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL, while Good management risk is found at Chemplast Sanmar. Average management risk is present at Tata Chemicals and India Glycols, while Below Average management risk is noted for Fischer Medical, Archit Organosys, and Sh. Hari Chem. Growth is classified as Good for Archit Organosys and Sh. Hari Chem., while Below Average growth is seen at Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, and Polychem. The rest have growth ratings that do not qualify. Capital Structure is Excellent at GHCL, Good at Fischer Medical and Polychem, Average at Tata Chemicals and Archit Organosys, and Below Average at Chemplast Sanmar and India Glycols.<BR><BR>Return Snapshot: India Glycols has the highest 1-year return at 150.46%, while Polychem has the lowest at -30.89%. Archit Organosys's 1-year return of 6.22% is significantly lower than India Glycols but higher than Polychem. Additionally, the six-month returns are negative for Tata Chemicals, Polychem, and Shreyas Interm.

What is the technical trend for Archit Organosys?

As of May 12, 2025, Archit Organosys shows a mildly bearish trend overall, with mixed signals from MACD and moving averages indicating short-term weakness despite some bullish signs on the weekly chart.

As of 12 May 2025, the technical trend for Archit Organosys has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands show a bullish signal on the weekly chart but are mildly bearish on the monthly. Daily moving averages are mildly bearish, suggesting short-term weakness. The KST is mildly bullish on the weekly but bearish on the monthly, and Dow Theory shows a mildly bullish trend on the weekly with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the mixed signals from MACD and moving averages.

Who are the top shareholders of the Archit Organosys?

The top shareholder of Archit Organosys is Archana Kandarp Amin, holding 22.44%. Individual investors own 30.78% of the company, with Shamoil Plumber as the largest public shareholder at 1.19%.

The top shareholders of Archit Organosys are primarily the promoters, with Archana Kandarp Amin holding the highest stake at 22.44%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) currently holding shares. Additionally, individual investors collectively own 30.78% of the company, with the highest public shareholder being Shamoil Plumber, who holds 1.19%.

How big is Archit Organosys?

As of 24th July, Archit Organosys Ltd has a market capitalization of 93.00 Cr, classifying it as a Micro Cap company, with recent Net Sales of 113.19 Cr and a Net Profit of 3.27 Cr. Specific values for Shareholder's Funds and Total Assets are unavailable.

As of 24th July, Archit Organosys Ltd has a market capitalization of 93.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Archit Organosys reported Net Sales of 113.19 Cr and a Net Profit of 3.27 Cr.<BR><BR>The reporting period for the balance sheet is the latest annual period, but specific values for Shareholder's Funds and Total Assets are unavailable.

How has been the historical performance of Archit Organosys?

Archit Organosys has experienced a declining trend in net sales and profits, with net sales dropping from 137.90 Cr in March 2022 to 113.19 Cr in March 2024, and profit after tax decreasing from 11.35 Cr to 3.28 Cr in the same period. Key financial metrics indicate a challenging performance, highlighted by a significant reduction in operating profit margin and earnings per share.

Answer:<BR>The historical performance of Archit Organosys shows a declining trend in net sales and profits over the past few years.<BR><BR>Breakdown:<BR>Archit Organosys reported net sales of 113.19 Cr in March 2024, a decrease from 127.78 Cr in March 2023 and 137.90 Cr in March 2022. The total operating income mirrored this decline, remaining at 113.19 Cr in March 2024 compared to 127.78 Cr in the previous year. The total expenditure, excluding depreciation, also decreased to 106.45 Cr in March 2024 from 108.90 Cr in March 2023. Operating profit (PBDIT) fell significantly to 9.18 Cr in March 2024 from 20.74 Cr in March 2023, reflecting a decrease in the operating profit margin from 14.78% to 5.95%. Profit before tax dropped to 4.32 Cr in March 2024, down from 15.36 Cr in March 2023, leading to a profit after tax of 3.28 Cr compared to 11.35 Cr the previous year. The earnings per share also declined to 1.6 in March 2024 from 5.53 in March 2023. Overall, the financial metrics indicate a challenging period for Archit Organosys, with declining revenues and profits over the years.

Is Archit Organosys overvalued or undervalued?

As of November 13, 2025, Archit Organosys is considered overvalued with a PE ratio of 147.70, significantly higher than its peers, and has underperformed the Sensex with a year-to-date return of -6.00%.

As of 13 November 2025, Archit Organosys' valuation grade has moved from attractive to fair. The company appears to be overvalued based on its current metrics. Notable ratios include a PE ratio of 147.70, an EV to EBITDA of 18.19, and a PEG ratio of 0.01, which suggests a significant disparity in growth expectations relative to its price.<BR><BR>In comparison to peers, Archit Organosys' PE ratio is substantially higher than that of Godrej Industries at 37.09, which is rated attractive, and Aarti Industries at 53.04, also rated fair. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -6.00% compared to the Sensex's 8.11%, further reinforcing the notion that Archit Organosys is currently overvalued.

When is the next results date for Archit Organosys Ltd?

The next results date for Archit Organosys Ltd is 07 February 2026.

The next results date for Archit Organosys Ltd is scheduled for 07 February 2026.

Why is Archit Organosys Ltd falling/rising?

As of 07-Feb, Archit Organosys Ltd's stock price is rising to Rs 41.49, driven by strong financial performance, increased investor participation, and favorable market conditions. Despite some long-term concerns, the stock has outperformed its sector and shows bullish momentum.

As of 07-Feb, Archit Organosys Ltd's stock price is rising, currently at Rs 41.49, reflecting a change of Rs 1.64 or 4.12% increase. This upward movement can be attributed to several positive factors. The stock has outperformed its sector by 4.92% today, indicating strong market interest. Additionally, the stock reached an intraday high of Rs 41.49, suggesting bullish momentum.<BR><BR>Investor participation has also increased, with delivery volume rising by 2.68% against the 5-day average, indicating growing confidence among investors. The company has reported positive financial results for the last four consecutive quarters, with a significant growth in profit after tax (PAT) of 76.35% over the last six months and a 24.80% increase in net sales for the first nine months. Furthermore, the stock is trading at a discount compared to its peers' average historical valuations, which may attract more investors.<BR><BR>Despite some long-term concerns, such as a weak average return on capital employed (ROCE) of 8.65% and slower growth in net sales over the past five years, the recent positive financial performance and favorable trading conditions have contributed to the stock's rise. Overall, the combination of strong quarterly results, increased investor participation, and favorable market conditions has led to the current upward trend in Archit Organosys Ltd's stock price.

Which are the latest news on Archit Organosys?

Are Archit Organosys Ltd latest results good or bad?

Archit Organosys Ltd's latest results show a significant profit increase of 628.93% for Q3 FY26, but concerns remain due to declining operating margins and a low return on equity of 0.97%. Investors should consider these mixed signals when evaluating the company's financial health.

Archit Organosys Ltd's latest results present a mixed picture. On one hand, the company achieved a significant turnaround in net profit for Q3 FY26, reporting ₹2.43 crores, which marks a remarkable 628.93% increase quarter-on-quarter. Additionally, revenue growth for the first half of FY26 was robust at 28.60% compared to the same period last year, indicating strong top-line performance.<BR><BR>However, there are notable concerns regarding profitability and operational efficiency. The operating margin has decreased to 7.69%, down from 10.48% in the previous quarter, reflecting ongoing margin compression. Furthermore, the return on equity (ROE) is critically low at just 0.97%, suggesting that the company is struggling to generate adequate returns for shareholders.<BR><BR>Overall, while the recent profit increase is encouraging, the underlying issues of declining margins and poor capital efficiency raise significant red flags. Investors should weigh these factors carefully when assessing the company's financial health and future prospects.

Should I buy, sell or hold Archit Organosys Ltd?